The Role of Hba1c In Severity and Mortality Rate of St Segment Elevation Myocardial Infarction For Hospitalized Libyan Non Diabetic Patients

Asgad Abdalgbar¹² and Hanan K.G. Altalhi¹

¹Faculty Of Medicine University Of Omar El Mukhtar Albayda - Libya
²Faculty Of Medical Technology University Of Omar El Mukhtar Albayda - Libya

Abstract: Background: The severity of coronary artery disease (CAD) is directly related to the quality of glucose control in diabetic patient. Additionally, diabetes is associated with increased mortality following acute myocardial infarction compared to general population. Objectives: To evaluate the association of HbA1c level and severity of CAD, and outcome of non-diabetic patient with STEMI in our hospital. Patients and methods: 60 consecutive non diabetic patient with acute ST elevation myocardial infarction were treated with thrombolytic therapy included in the present prospective study. Blood glucose and HbA1c level of all patients were measured within 3 hours of admission. Patient were divided in to 3 groups according to HbA1c level: with cut-off 6.5% as diagnostic criteria of diabetes mellitus according to (American diabetes association) group (1) 6.5%, group (2) 6.5 to 8.5%, group (3) 8.5% and above. In hospital mortality and morbidities of acute STEMI were compared between groups. Result: The mean age was 63±15 year and mean body mass index was 26.6±6 kg/m², 24 patients (40%) had history of hypertension, 27 patients (45%) of dyslipidemia, 36 patients (60%) were smoker. We found 45 patients with HbA1c ≤ 6.5%, 5 patients with HbA1c 6.5–8.5%, 10 patients with HbA1c ≥ 8.5%. There was strong correlation between admission of HbA1c and admission glucose level (P<0.001). Infarct size as measured by peak creatinin kinase, was not correlated with HbA1c level. Conclusion: HbA1c is an important risk marker in the absence of history of diabetes mellitus in patients with AMI. The optimal management in these patients may contribute in decrease hospital mortality.

Keywords: Glycosylated Hemoglobin (HbA1c); ST elevation myocardial infarction (STEMI); mortalities; Diabetes.

INTRODUCTION:

Patients with diabetes are at 3-4 times increased risk for cardiovascular mortality compared with non-diabetes (Preis PR et al., 2009). In acute coronary syndrome, glucose metabolism is modified and stress hyperglycemia commonly occur secondary to increase catecholamine level (Husband DJ et al., 1983). In addition to the higher rate of acute ST- elevation myocardial infarction (STEMI) in diabetes, hyperglycemia is associated with poor prognosis in these patients (Wahab N et al., 2002; Wiviott S et al., 2008; Li D et al., 2011).

Higher HbA1c level was associated with high cardiovascular disease and death (Selvin E et al., 2010). There were some other studies supporting the association between admission serum HbA1c level and increased long-term mortality of non-diabetic patients admitted with STEMI and higher rate CAD in these patients (Timmer J et al., 2011, Pia J et al., 2013). We have evaluated the association of admission level of HbA1c with the
hospital outcome of non-diabetic patient with STEMI.

**PATIENTS AND METHODS:**

All patients of both sexes sustaining acute ST elevation myocardial infarction without diabetes were included in the study. Patients with sepsis, hemoglobinopathies or hypothyroidism, tumor, connective tissue diseases, those with sub-acute or chronic MI (longer than 48 hr between first symptom and admission) those with renal failure, hepatic failure, iron deficiency anemia and those with past history of diabetes or used anti diabetic medication were excluded from the study.

Acute myocardial infarction was defined according to the (European Society of Cardiology and American College of Cardiology Criteria).

Increased creatine kinase predominantly in the myocardial band fraction and or increased troponin I (creatine kinase 400 U/L or higher and or cardiac troponin I 2 µg / L or higher) , ischemic symptoms (mainly constrictive chest pain, lasting longer than 30 min) , and or abnormal electrocardiography (ST elevation 1 mm or greater on at least two derivation) . MI was defined as acute if the time elapsed between the first symptom and admission was 48 hr or less .only patients who underwent thrombolytic treatment were included in the study.

All patients were in cardiac care unit , a brief history was obtained from each patient presenting with acute chest pain including presence of risk factors like smoking and hypertension, dyslipidemia and previous history of ischemic heart disease . Clinical examination was done emphasis on signs of cardiac failure , 12 leads electrocardiography (ECG) was done at cardiac care unit and blood sample were sent to laboratory, blood glucose and HbA1c level of all patients were measured within 3 hr of admission regardless of whether they had been fasting or not and for cardiac enzyme. The fasting lipid profile was determined on the morning following admission and included total cholesterol , high density lipoprotein and triglyceride.

All patients were considered for thrombolytic therapy (Injection streptokinase 1.5 million units over one hour) in the absence of all contraindication the management was according to standard treatment protocol. All patients underwent continues ECG monitoring for at least 48 hour on admission to cardiac care unit and daily during hospital stay.

Patients were divided into three groups according to the level of HbA1c with cut-off 6.5% as diagnostic criteria of diabetes mellitus according to (American Diabetes Association 2010) for diagnosis and classification of diabetes mellitus. Patient with HbA1c level of 4.5% to 6.4 % group (1), patients with HbA1c level 6.5% to 8.5% group (2) and patients with HbA1c level higher than 8.5 % group 3).

None of these patients received glucose , Insulin or potassium infusion therapy during admission. All subjects were hospitalized one week after acute myocardial infarction and hospital records were reviewed at this time.

Selective coronary angiography was performed after 1 month .Coronary angiogram were analyzed by two experienced observers who were blinded to the identities and clinical information of the patients .Vessel scores were ranged from zero to three, according to the number of diseased major pericardial vessel with significant stenosis (greater than 50% stenosis of the lumen diameter).

Statistical analysis: Was performed by using SPSS software (Version 12 ) difference among groups was analyzed by (t-test) and P value 0.05 was considerable significant.

**RESULT:**

Table 1: Total 60 patients with STEMT were studied . Patients were divided on the bases of admission HbA1c group (1) ≤ 6.5 %; group (2) 6.5-8.5 %; group 3 ≥ 8.5%.

<table>
<thead>
<tr>
<th>Group of Glycated Hemoglobin</th>
<th>Level of Glycated Hemoglobin</th>
<th>Group1 ≤6.5% N=45</th>
<th>Group2 6.5-8.5% N=5</th>
<th>Group3 &gt;8.5% N=10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(year)</td>
<td>All n=60</td>
<td>63±15</td>
<td>61±15</td>
<td>60±17</td>
</tr>
<tr>
<td>Sex(M/F)</td>
<td>48/12</td>
<td>40/5</td>
<td>3/2</td>
<td>7/3</td>
</tr>
<tr>
<td>Current or former smoker(%)</td>
<td>36(60)</td>
<td>29(55)</td>
<td>2(40)</td>
<td>6(60)</td>
</tr>
<tr>
<td>BMI(kg/m²)</td>
<td>26.6±6</td>
<td>26.1±5</td>
<td>26.7±4.2</td>
<td>29±4.9</td>
</tr>
<tr>
<td>Admission SBP(mmHg)</td>
<td>132±25</td>
<td>129±25</td>
<td>136±22</td>
<td>143±25</td>
</tr>
<tr>
<td>Admission DBP(mmHg)</td>
<td>72±18</td>
<td>72±15</td>
<td>71±14</td>
<td>76±23</td>
</tr>
<tr>
<td>Admission plasma glucose(mmm/L)</td>
<td>8.2±3.7</td>
<td>7.7±2.9</td>
<td>8.2±2.2</td>
<td>11.2±6.5</td>
</tr>
<tr>
<td>Total cholesterol(mmm/L)</td>
<td>6±1.2</td>
<td>6±1.3</td>
<td>6.3±0.9</td>
<td>5.5±1.1</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1±0.4</td>
<td>1.3±0.4</td>
<td>1.2±0.1</td>
<td>1.2±0.3</td>
</tr>
</tbody>
</table>
Data are mean ± SD, BMI, body mass index (kg/m²). SBP/DBP, systolic/diastolic blood pressure; CK, Creatinin kinase.

The clinical and biological characteristics according to HbA1c are summarized in (table 1). The mean age was 63 ± 15 year and mean body mass index was 26.6 ± 6 kg/m². 24 (40%) had history of hypertension, 27 (45%) of dyslipidemia, 36 (60%) were smoker. We found 45 with HbA1c < 6.5%; 5 with HbA1c 6.5-8.5%; 10 with HbA1c ≥ 8.5%.

Table 2: Clinical outcome of non-diabetic patients based on quantities of admission plasma glucose.

<table>
<thead>
<tr>
<th>Admission Glucose Level</th>
<th>P Value</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Group 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mmol/L)</td>
<td></td>
<td>&lt;6.5%</td>
<td>6.5%-8.5%</td>
<td>&gt;8.5%</td>
<td>&gt;9.6%</td>
</tr>
<tr>
<td>N=39</td>
<td>0.15</td>
<td>0.0001</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td>Infarct size (mmol/L)</td>
<td></td>
<td>1912 (827-3256)</td>
<td>1367 (564-2924)</td>
<td>903 (327-2905)</td>
<td>530 (210-1150)</td>
</tr>
<tr>
<td>Peak.CK in the first 24 hr(U/L)</td>
<td>&lt;0.0001</td>
<td>451 (827-3256)</td>
<td>341 (564-2924)</td>
<td>271 (327-2905)</td>
<td>130 (210-1150)</td>
</tr>
</tbody>
</table>
| IQR = interquartile range; CK= creatinin kinase. Value are expressed as median(IQR).

There was significant positive correlation between admission glucose and infarct size measured by peak creatinin kinase level (P<0.0001).

Table 3: Angiographic data of patients according to HbA1c

<table>
<thead>
<tr>
<th>Level of Glycosylated Hemoglobin</th>
<th>Number of diseased vessel N (%)</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (&lt;6.5%)</td>
<td>N=39</td>
<td>1(10%)</td>
<td>7(1.7%)</td>
<td>1(10%)</td>
<td>0.000</td>
</tr>
<tr>
<td>HbA1c (6.5%-8.5%)</td>
<td>N=5</td>
<td>1(20%)</td>
<td>2(5.1%)</td>
<td>1(20%)</td>
<td>0.001</td>
</tr>
<tr>
<td>HbA1c (≥8.5%)</td>
<td>N=10</td>
<td>1(20%)</td>
<td>5(50%)</td>
<td>12(20%)</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Table 4: We found that patients who died by day 5 were significantly different from patients with non-lethal acute myocardial infarction, with regard to admission plasma glucose (16.6 ± 5.4 vs 8.3 ± 3.4 mmol/L, P=0.0001), age (74±10 vs 62 ± 13 year, P=0.002).

Table 4: Clinical characteristics of patients according to the mortality at 5 days after acute myocardial infarction.

| Age(year) | N=6 | 74±10 | 62 ± 13 | 0.002 |
| Sex (M/F) | 6/0 | 42/12 | 0.33 |
| Peak creatinin kinase (IU/L) | N=54 | 1068 (1120-3256) | 825 (210-1860) | 0.02 |
| Admission plasma glucose (mmol/L) | N=54 | 16.6 ± 5.4 | 8.3 ± 3.4 | 0.0001 |
| HbA1c | 6.7 ± 1.8 | 6.2 ± 0.2 | 0.15 |

HbA1c=Glycosylated hemoglobin

There was no significant difference in HbA1c value in the survivor and non-survivor (6.7±1.8 vs 6± 0.2, P=0.15).
DISCUSSION:

The present study confirms previous observation in diabetic subjects suggesting that higher glucose level during AMI are associated with increased mortality (Sewaradsen M, et al 1989). In recent study, (Timmer J, et al, 2011) reported that higher admission glucose level in non-diabetic patients treated with reperfusion therapy for ST segment elevation MI were associated with significantly larger enzymatic infarction size and lower left ventricular ejection fraction. This is because a stress response is accompanied by high level of catecholamine and cortisol and these hormones increase glucogenolysis and lipolysis and reduce insulin sensitivity, resulting in elevated glucose level (Seaquist ER, et al., 2013) There for, patients with elevated glucose level may represent with an increased stress response, due to more sever hemodynamic compromise or more extensive myocardial damage (Gosselink AT, et al., 1998; DeGeare V S, et al., 2001). Elevated cytokine, particularly tumor necrosis factor-alpha (TNF-α), also increase glucose level. TNF-α is released in AMI and directly decrease myocardial contractility, probably by inducing myocardial apoptosis (Li D, et al., 1999; Li YP et al., 2001). TNF-α also cause impaired endothelial function (Fujita H, et al., 1999). This in turn, may be responsible for the impaired myocardial perfusion. We found positive correlation between peak creatinin kinase and admission plasma glucose concentration in our patients. Conversely, no correlation was found with HbA1c value. Although acute hyperglycemia at admission and during stay has clearly been associated with adverse outcome in patients with acute MI (Capes E, et al., 2000; Norhmmar A, et al., 2002; Timmer J, et al., 2004).

Our study shows admission HbA1c level are not associated with high mortality in non-diabetic STEMI population treated with streptokinase. In our study high HbA1c in non-diabetic patients associated with multivessel involvement of coronary arteries. Similarly (Cakmak, et al., 2008) reported a significant correlation between HbA1c level at admission and positive exercise that result after the four week follow up.

Hyperglycemia in STEMI patients was strongly associated with increased mortality within 5 days although there is clear correlation between admission glucose and HbA1c level, they appear to represent related but different phenomena. Patients with elevated glucose level have larger MI area.

Recently a prospective cohort study showed that in non-diabetic general population, as elevated HbA1c level is a risk factor for the development of cardiovascular events independently of fasting glucose (Selvin E, et al., 2009). The international expert committee recommended the use of HbA1c in diagnosis diabetes with a cut-off 6.5 % (Gillet M, et al., 2009).

The advantage of HbA1c over the fast blood glucose are its lower intra-individual variability, assessment in non-fasting state and superior in monitoring blood glucose level (Selvin et al., 2007; American Diabetes Association, 2009). (Preis et al., 2009 Selvin et al, 2010) has suggested that glycosylated hemoglobin is superior to fasting blood glucose in predicting long-term risk of CAD in non-diabetes. Similar result are reported by Park and colleagues among non-diabetic women (Park et al., 1996). In a cohort of European men, khaw and colleagues reported that HbA1c correlates linearly to subsequent cardiovascular morbidity, (Khaw et al., 2001). The American Diabetes Association suggests that individual with HbA1c concentration of 5.7-6.4% should be informed of their increased risk for diabetes as well as cardiovascular disease (American Diabetes Association 2010).

CONCLUSION:

HbA1c is an important risk marker in the absence of history of diabetes mellitus in patients with AMI. The optimal management in these patients may contribute in decrease hospital mortality. People at high risk for type II diabetes mellitus should receive lifestyle counseling and if needed pharmacological therapy to reduce their risk of developing hyperglycemia and type II diabetes mellitus but especially to prevent or slow the development of CAD.

REFERENCES:
